Alpha-1 Antitrypsin Deficiency Clinical Trial
Official title:
The Role of Conformational Diseases on Macrophage Function
The purpose of this study is to look at how Alpha-1-antitrypsin (AAT) deficiency and Cystic Fibrosis (CF) affect white blood cells in the lungs, called macrophages, and their ability to work.
AAT deficiency is a genetic disorder that affects around 100,000 people in the USA, including 1-3% of all people diagnosed with chronic obstructive pulmonary disease (COPD). In AAT deficient people diagnosed with COPD, it was originally believed the cause of the disease was due to a lack of supply of alpha-1 antitrypsin. However, early information gathered in our laboratory suggests another cause of the development of COPD and the progressing of the disease may be due to a malfunction in macrophages. CF is also a genetic disorder which affects 1/300 births among the Caucasian population. One of the main symptoms of CF is inflammation of the lung tissue. Lung macrophages play a major role in lung inflammation as well as in helping to resolve the inflammation. Inflammation is an important defense of the body. It is the body's response to infection causing germs and things that may cause irritation, as well as, a way for the body to repair damaged tissue. We suggest that the effects of AAT deficiency and CF decreases the inflammation response in the lungs and also restricts the ability of macrophages to correct that inflammation once it occurs. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02547532 -
Microbioma in Sputa From COPD With Alpha-1 Antitrypsin Deficiency
|
||
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT00005292 -
Alpha1-antitrypsin Deficiency Registry
|
N/A | |
Withdrawn |
NCT02900183 -
Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels
|
Phase 2 | |
Terminated |
NCT02502201 -
Environment Effect on Six-Minute Walk Test Performance
|
N/A | |
Completed |
NCT01810458 -
Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
|
||
Active, not recruiting |
NCT04262284 -
Respreeza® Self-administration and Learning Program (AmAREtTI Study)
|
||
Recruiting |
NCT06186492 -
A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1)
|
Phase 1 | |
Recruiting |
NCT06405633 -
A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD
|
Phase 1/Phase 2 | |
Completed |
NCT01054339 -
Safety & Efficacy Study of rAAV1-CB-hAAT for Alpha-1 Antitrypsin Deficiency
|
Phase 2 | |
Completed |
NCT03815396 -
Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency
|
Phase 1 | |
Completed |
NCT03008915 -
Targeting Pulmonary Perfusion in Alpha-1 Antitrypsin Deficiency
|
Phase 2 | |
Completed |
NCT01419158 -
Prevalence of Alpha-1 Antitrypsin Deficiency in Chronic Obstructive Pulmonary Disease (COPD)
|
N/A | |
Recruiting |
NCT00500123 -
The Alpha-1 Foundation's and University of Florida's Alpha-1 Coded Testing (ACT) Study
|
||
Completed |
NCT05727800 -
A Phase 1, First-in-human Study of VX-668
|
Phase 1 | |
Active, not recruiting |
NCT05643495 -
A Study to Evaluate Efficacy and Safety of VX-864 in Participants With the PiZZ Genotype
|
Phase 2 | |
Terminated |
NCT02363946 -
A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)
|
Phase 1 | |
Completed |
NCT02810327 -
Alpha-1 Carrier Genomics Study
|
||
Completed |
NCT03804021 -
Long-Term Follow-up Study of ADVM-043
|
||
Active, not recruiting |
NCT02014415 -
Alpha-1 Antitrypsin Deficiency Adult Liver Study
|